Materials and Methods
Statistical Analysis
Results
Age (mean ± SD) | 53.80 ± 11.58 |
BMI (mean ± SD) | 24.57 ± 4.26 |
Hystotipe | |
Serous papillary | 55 (82%) |
Endometrioid | 3 (4.5%) |
Clear cell | 4 (6%) |
Other | 5 (7.5%) |
Grading | |
G1 | 2 (3%) |
G2 | 14 (20.9%) |
G3 | 51 (76.1%) |
FIGO stage | |
IIIC | 45 (67.1%) |
IV | 22 (32.9%) |
Preoperative albumine (g/dL) | 4.2 (2.2–5.7) |
Preoperative Hemoglobin (g/dL) | 12.7 ± 1.19 |
Preoperative Ca 125 (U/ml) | 687.52 ± 100.8 |
Surgery | |
PDS | 41 (61.2%) |
IDS | 26 (38.8%) |
Inpatients day | 8 (5–22) |
Operative time | 297 ± 110 |
Hepatic | 55 (82.1%) |
Intraparenchymal | 20 (29.8%) |
Glisson’s capsule | 35 (52.3%) |
Biliary tract | 20 (29.8%) |
Celiac lymph node | 6 (8.9%) |
Common hepatic arteries | 3 (4.5%) |
Portal vein | 3 (4.5%) |
Hepatobiliary procedures | |
Hepatic surgery | |
Liver resection | 20 (29.8%) |
Glisson resection | 35 (52.3%) |
Biliary surgery | |
Biliary tract | 20 (29.8%) |
Celiac lymphadenectomy | 6 (8.9%) |
Hepatic artery | 3 (4.5%) |
Portal vein nodes | 3 (4.5%) |
Associated procedures | |
Diaphragmatic surgery | |
Peritoneal | 18 (26.5%) |
Resection | 9 (1.2%) |
Pancreatectomy | 16 (23.9%) |
Splenic surgery | 20 (29.4%) |
Gastric surgery | 2 (2.9%) |
Lymphadenectomy | |
Pelvic | 6 (8.8%) |
Para-aortic | 10 (14.7%) |
Pelvic + para-aortic | 4 (5.9%) |
Rectal surgery | 23 (33.8%) |
Ileum surgery | 33 (48.5%) |
Large bowel surgery | 16 (23.5%) |
Accordion score | Total (n = 67) | High complexity (n = 44) | Intermediate complexity (n = 23) |
---|---|---|---|
0 (No complication) | 28 (41.8%) | 13 (29.5%) | 15 (65.2%) |
Mild complication (G1–G2) | 30 (44.8%) | 22 (50%) | 8 (34.8%) |
Severe complication (G3–G5) | 7 (10.4%) | 7 (15.9%) | 0 |
90-Day mortality | 2 (2.98%) | 2 (4.5%) | 0 |
Discussion
References | No. patients | Stage of disease | Liver resection, n (%) | PH resection, n (%) | No RT | No RT in liver and PH area | Morbidity (classification) | Morbidity related to LIVER or PH (classification) |
---|---|---|---|---|---|---|---|---|
Bristow et al.16 | 84 Primary | IV 84 (100%) | 37 (44%) | – | 30% RT < 1 | 16% RT < 1 | Overall: 32% Mortality: 6% | – |
Chia et al.20 | 70 Primary | III 59 (84%) IV 11 (16%) | 3 (4.3%) | 3 (4.3%) | 76% RT < 1 | – | G1–2: 50% G3–5: 6% Mortality: 0.7% MSKCC | – |
Eisenhauer et al.21 | 57 Primary | III 41 (72%) IV 16 (28%) | 9 (16%) | 8 (14%) | 13 (23%) | – | Overall 7 (12%) | – |
Chi et al.22 | 141 Primary | III 103 (73%) IV 38 (27%) | 18 (13%) | 14 (10%) | 42 (30%) | – | G3–5 31 (22%) Mortality: 1.4% | – |
Song et al.23 | 101 Primary 54 Recurrence | – | 6 (3.9%) | Primary 2 (1.9%) Recurrence: 9 (16.7%) | 144 (100%) | 10 (90.9%) | Any G: 4 (4%) Mortality: 0% | 0% |
Martinez et al.17 | 20 Primary 8 Recurrence | III 22 (78.5%) IV 6 (21.5%) | 7 (25%) | 2 (7.1%) | 27 (96.4%) | – | – | G3–5 10 (35.7%) Mortality: 1 (3.6%) CTCAE, 2009 |
Raspagliesi et al.19 | 37 Primary | III 29 (78.3%) IV 8 (21.7%) | 3 (8.1%) | 4 (10.8%) | 34 (91.9%) | – | G1–3 8 (21.6%) Mortality 0% CTCAE, 2010 | – |
Rodriguez et al.24 | 482 Primary | III 392 (81.3%) IV 90 (18.7%) | 112 (23.2%) | 7 (0.2%) | 141 (29.3%) | – | – | – |
Martinez et al.25 | 34b Primary 7b Recurrence | III 32 (78%) IV 9 (22%) | – | 41 (100%)b | 40 (97.6%) | – | – | – |
Benedetti Panici et al.26 | 121 Primary | III 96 (79.4%) IV 25 (20.6%) | 48 (40%) | 24 (19.8%)c | 91 (75.1%) | – | G1–2 22 (17.8%) G3–4 23 (19%) Mortality: 0.7% CTCAE, 2009 | – |
Tozzi et al.12 | 31 Primary | III 24 (77.4%) IV 7 (22.6%) | – | 31 (14.3%)b | – | 28 (90.3%) $ | G3: 3 (23.1) Mortality 0% Clavien-Dindo | – |
Gallotta et al.27 | 85 Primary | III 77 (90.6%) IV 8 (9.4%) | 8 (9.4%) | – | 73 (85.9%) | – | Overall: 58 (68.2%) G3–G4: 30(51.7%) Mortality: 3.5% MSKCC | – |
Harter et al.15 | 647 Primary | I to IIa 32 (4.9%) IIb to IIIa 93 (14.4%) IIIb to IV 505 (77.7%) | 55 (8.5%) | 130 (20.1%)d | 643 (99.4%)e | – | Overall: 495 (76.5%) Mortality: 2% | . |
Angeles et al.28 | 43 Primary | III 36 (83.7%) IV 7 (16.3%) | 8 (18.6%) | 22 (51.2%) | 43 (100%) | 43 (100%) | G3–5: 13 (30.2%) Mortality 0% Clavien-Dindo | 0% |